A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in
combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with
refractory or relapsed osteosarcoma ( combination Sulfatinib).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Chonnam National University Peking University People's Hospital Qilu Hospital of Shandong University Ruijin Hospital Shanghai Jiao Tong University Affiliated Sixth People's Hospital